If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
28.50    0.30 (1.06%)
Bid:
28.00
Ask:
29.00
Spread: 1.00 (3.571%)
Market Cap: £51.54m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Goliath P1 Cells Validated by Customer Testing

1 May 2025 07:00

RNS Number : 8702G
Ilika plc
01 May 2025
 

Ilika plc

("Ilika", the "Group", or the "Company")

 

Goliath P1 Cells Validated by Customer Testing

 

Ilika (AIM: IKA), an independent global expert in solid-state battery technology, announces that it has received confirmation from OEM and Tier 1 testing partners that its P1 Goliath prototypes perform to specification.

 

Further to its RNS of May 2024 announcing commencement of testing of P1 prototype cells on behalf of, and subsequently by, commercial partners, Ilika confirms that the suite of tests including cell formation protocol, measurement of energy capacity, charge rate, power delivery capability and accelerated cyclability have confirmed the specification of its P1 cells. Furthermore, the tests demonstrated good reproducibility across the batch and delivered the expected electrochemical signature.

 

The tests were carried out under commercial agreements with confidentiality provisions designed to protect proprietary duty cycle protocols owned by the OEMs and Tier 1 companies. The test protocols used are representative of those used to evaluate batteries for electric vehicles and, while the protocols vary from one partner to another, the results have been consistent, and they are globally relevant.

 

The Head of Battery Development at an UK-based electrification Tier 1 supplying global OEMs, stated, "We can confirm that we have completed testing of Ilika's P1 prototypes and they perform to specification, putting them in the cohort of leading solid-state batteries we have tested. We look forward to evaluating further prototypes as Ilika progresses through its roadmap."

 

Graeme Purdy, Ilika CEO, stated, "Customer validation of our Goliath roadmap is of primary importance to us to ensure that we are progressing towards a minimum viable product that meets or exceeds customer expectations. Clearly, this set of validations increases our confidence in the attractiveness of our roadmap. We will continue to engage with a portfolio of potential manufacturing partners to minimise commercialisation risk."

 

In parallel with the validation programmes carried out on its P1s, Ilika has continued to develop its batteries as outlined in its 2024 annual report. In October 2024, Ilika announced compelling safety test data validated by the Faraday Institution's Safebatt programme. Ilika is currently conducting in-house testing of larger 10Ah cells associated with its materials design freeze before releasing its 10Ah (P1.5) prototypes in H2 CY25. Ilika's near-term roadmap extends through to 50Ah minimum viable product (MVP), with the first release expected at the end CY25. Ilika's Goliath MVP, or P2 prototypes, will underpin licensing opportunities.

 

ENDS

 

--

Enquiries:

 

Ilika Plc Graeme Purdy, Chief Executive

Jason Stewart, Chief Financial Officer

 

www.ilika.com

Via FTI Consulting

 

Cavendish Capital Markets Limited (Nomad and Broker) Peter Lynch

Neil McDonald

 

+44 (0)131 220 9772

+44 (0)131 220 9771

 

FTI Consulting (Comms Advisors)

Ben Brewerton

Elizabeth Adams

Dwight Burden

ilika@fticonsulting.com

 

 

About Ilika plc - https://www.ilika.com

 

Ilika is a global expert in the development of solid state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFBLFXEZLZBBF
Date   Source Headline
12th Nov 20137:00 amRNSHalf Year Trading Update
28th Oct 20137:00 amRNSIlika expands into Aerospace Sector
21st Oct 20137:00 amRNSInvestor Teach-in
17th Sep 20134:09 pmRNSResult of AGM
17th Sep 20137:00 amRNSAGM Statement
16th Sep 20137:00 amRNSTwo New Customers in Europe
23rd Aug 20131:25 pmRNSPosting of Annual Report & Notice of AGM
2nd Aug 20135:02 pmRNSConversion of Securities
30th Jul 20137:00 amRNSContract Renewals and Grant Award
19th Jul 20132:50 pmRNSHolding(s) in Company
19th Jul 201311:17 amRNSHolding(s) in Company
18th Jul 20137:00 amRNS£3.3 million EPSRC Grant Award to Southampton Univ
15th Jul 20137:00 amRNSFinal Results
21st May 20131:09 pmRNSHolding(s) in Company
20th May 20137:00 amRNSDirectorate Change and Conversion of Securities
17th May 20133:57 pmRNSPlacing - Replacement
17th May 20137:00 amRNSPlacing
1st May 20137:00 amRNSFuel Cell Catalyst Patent Granted in Japan
22nd Apr 20137:00 amRNSContract with new European Customer
16th Apr 20137:00 amRNSTrading Update
21st Feb 20137:00 amRNSRenewal of Contract
29th Jan 20137:00 amRNSCompletion of Laboratory Facility Expansion
18th Jan 20133:28 pmRNSHolding(s) in Company
17th Jan 20135:46 pmRNSHolding(s) in Company
17th Jan 201311:16 amRNSHolding(s) in Company
15th Jan 20135:21 pmRNSHolding(s) in Company
10th Jan 20137:00 amRNSInterim Results
21st Dec 20127:00 amRNSGrant of Fuel Cell Catalyst Patent
18th Dec 20121:41 pmRNSCompletion of Disposal
17th Dec 20127:00 amRNSConversion of Securities
11th Dec 20127:00 amRNSRenewal of Contract
29th Nov 20124:44 pmRNSHolding(s) in Company
28th Nov 20125:00 pmRNSHolding(s) in Company
27th Nov 20122:18 pmRNSHolding(s) in Company
19th Nov 20127:00 amRNSEnergizer Relationship Update
22nd Oct 20127:00 amRNSTrading Update
5th Oct 20127:00 amRNSHolding(s) in Company
5th Oct 20127:00 amRNSTotal Voting Rights
18th Sep 20127:00 amRNSDiscontinuing of wound care products and services
14th Sep 20127:00 amRNSCarbon Trust Investment
7th Sep 20121:27 pmRNSResult of AGM
7th Sep 20127:00 amRNSAGM Statement
9th Aug 20127:00 amRNSPosting of Annual Report & Notice of AGM
19th Jul 20127:00 amRNSFinal Results
14th Jun 20127:14 amRNSChange of Adviser
1st Jun 201210:01 amRNSTotal Voting Rights
18th May 20127:00 amRNSTrading Update
17th May 20127:00 amRNSConversion of Securities
2nd May 20127:00 amRNSVapour Deposition Method US Patent Grant
1st May 20123:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.